The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.

Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help leaders become strategically authentic, writes Hope Mueller.

On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...

Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

Life sciences organizations invest heavily in marketing visibility. Most maintain a website, actively use LinkedIn, and participate in industry events. These efforts signal credibility, momentum, and ...

Small and mid-cap biotechs face a fundamental strategic choice that will determine their survival in this new world of business. How will they compete against well-capitalized incumbents while ...

Ocular endpoints often introduce unique operational bottlenecks—such as referral delays and capacity limits—that can stall enrollment and compromise data integrity. This presentation features Jessica ...

Artificial intelligence is reshaping life sciences, but deciding whether to build or buy AI solutions can be complex. This guide explores the critical factors behind each approach, helping ...

The FDA has approved the first oral GLP-1 treatment for obesity in the U.S.—Novo Nordisk’s Wegovy pill. This once-daily medication represents a major advancement in weight management, offering an ...

The 2025 Regulatory-Industry Statistics Workshop (RISW) highlighted a pivotal shift toward integrating artificial intelligence with traditional statistical frameworks to streamline drug development.